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869-3 Aqueous Oxygen Therapy for ST Segment Elevation 
Myocardial Infarction: AMIHOT Trial Safety Report and 
Enrollment Completion
Jack L. Martin, Francis Day, Simon Dixon, Douwe Atsma, Pranobe Oemrawsingh, 
Catherine Pensyl, Barbara Lindsay, Antonio Bartorelli, William O'Neill, Main Line Health 
System, Bryn Mawr, PA, William Beaumont Hospital, Royal Oak, MI
Background: Although rapid coronary reperfusion in ST segment elevation myocardial
infarction (STEMI) improves left ventricular function and mortality, epicardial vessel
patency does not fully ensure nutrient flow at the tissue level. Animal and Phase I human
testing of the TherOx® Aqueous Oxygen (AO) System (TherOx Inc., Irvine, California)
suggests that percutaneous coronary infusion of autologous blood mixed with hyperox-
emic saline may help overcome the downstream barrier to oxygen delivery in ischemic
zones and improve myocardial salvage following percutaneous intervention for STEMI.
Methods: A Phase II randomized international trial is designed to evaluate the efficacy of
regional AO therapy in STEMI.A sub-selective catheter positioned in the infarct artery
delivers AO for 90 minutes at 75 ml/minute. Contrast echocardiography performed follow-
ing intervention and before randomization is repeated at 24 hours, and days 30 and 90.
Resting SPECT myocardial perfusion scans are obtained day 14. Primary endpoints
include regional wall motion scores, SPECT perfusion defects, and ST segment resolu-
tion.
Results: Two hundred patients have been randomized after 20 run-in cases. None of the
100 patients assigned to treatment experienced hemodynamic or electrophysiologic
instability during infusion. Repeat angiography when performed following AO therapy
documented perfusion catheter stability and maintenance of TIMI 3 flow. Planned interim
analysis performed after randomization of the first 200 patients demonstrated no safety
concerns and there were no unanticipated major cardiac events. Enrollment of the 270
patient cohort is to be completed by January, 2003.
Conclusion: Preliminary results suggest that regional hyperoxemic therapy appears to
be safe and can be readily applied in institutions performing primary angioplasty for
STEMI. Conclusions regarding the promise of this new therapeutic modality to improve
recovery of left ventricular function requires longer-term follow up.
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869-4 Sex Disparities in the Treatment of Non–ST-Segment 
Elevation Acute Coronary Syndromes
Andra L. Blomkalns, L. Kristin Newby, Anita Chen, Eric D. Peterson, Kelly Trynosky, 
Deborah Diercks, William E. Boden, Matthew T. Roe, E. Magnus Ohman, W. Brian Gibler, 
Judith S. Hochman, University of Cincinnati, Cincinnati, OH, Duke Clinical Research 
Institute, Durham, NC
Background: No large-scale examination of sex disparities in the management of acute
coronary syndromes (ACS) has been done since publication of the revised ACC/AHA
Guidelines for the Diagnosis and Treatment of non–ST-elevation acute coronary syn-
dromes (NSTE ACS).
Methods: We conducted a retrospective data analysis from the CRUSADE Initiative,
which enrolls US pts with NSTE ACS (ST-segment depression or transient elevation or
positive cardiac markers). We examined sex differences in the use of acute and dis-
charge medications, in-hospital procedures, discharge interventions, and in-hospital out-
comes.
Results: Of the 35,835 pts (41% women) in the study, women were older and had more
diabetes and hypertension but less prior MI or revascularization (Table). Women less
often received acute aspirin, heparin, GP IIb-IIIa or ACE inhibitors. Discharge treatments
were similarly disparate for use of aspirin, beta blockers, ACE inhibitors, and statins.
Women were at higher risk for death (5.6% vs 4.3%, p<0.0001), post-admission MI (4.0%
vs 3.5%, p=0.03), CHF (12.1% vs 8.8%, p<0.0001), stroke (1.1% vs 0.8%, p<0.003), and
RBC transfusion (17.2% vs 13.2%, p<0.01).
Conclusion: Despite having higher-risk characteristics at presentation and greater in-
hospital risk, women with NSTE ACS are consistently treated less aggressively than
men. Lower use of evidence-based therapies was observed in women even after adjust-
ing for important differences between groups.
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869-5 Primary Angioplasty Is More Cost-Effective Than 
Prehospital Thrombolysis for Patients Within 90 
Minutes From a Percutaneous Coronary Intervention 
Center: One-Year Follow-Up of a CAPTIM Substudy
Gerald Vanzetto, Eric Bonnefoy, Helene Bouvaist, Stephanie Marliere, Jean Cassagnes, 
Paul Touboul, Jacques Machecourt, The CAPTIM Study Investigators, University 
Hospital, Grenoble, France
Background: In the CAPTIM study, primary coronary angioplasty (PCA) was as efficient
as pre-hospital thrombolysis (PHT) in patients (pts) with acute myocardial infarction (MI)
within 90 minutes from a coronary intervention (PCI) center. We compared the in-hospital
and 1 year cost-effectiveness of PCA and PHT in a predefined subset of pts from the
CAPTIM study.
Methods: 299 consecutive pts were used for analysis (PCA n=149, PHT n=150, men
80%, mean age=59±12 yrs, anterior wall MI 46%). For each pts, real costs were obtained
for pre-hospital care, key hospital resources, medications, biological and X-rays examina-
tions, catheterization devices, and staff. One year cumulative costs included costs of ini-
tial hospital, plus medications, rehabilitation, examinations, angiographies,
revascularizations and re-hospitalizations occuring after the acute phase.
Results: The 2 groups were similar for baseline data and characteristics of MI. Initial
hospitalization was shorter after PCA than after PHT (9.5 vs. 10.5 days, p=0.009), due to
more frequent emergent or planned angioplasty in the PHT group (42% vs 10%
p<0.001). Median in-hospital real cost were 6097 and 6857 € in the PCA and PHT
respectively (p=0.008). Results at 1 year follow-up (100% completed) are listed bellow.
Conclusion: When compared to PHT, PCA is a dominant strategy for treatment of MI in
pts within 90 minutes of a PCI center, driven by a shorter in-hospital stay and a significant
reduction of non planned revascularizations.
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869-6 Beneficial Effects of Combined Thrombolytic Therapy 
and Percutaneous Coronary Angioplasty in Transfer 
Patients With ST Segment Elevation Myocardial 
Infarction: A Report From the American College of 
Cardiology-National Cardiovascular Data Registry
Daniel P. O'Neill, Peter Y. M. Hui, Rupsa R. Yee, Richard Gray, Richard E. Shaw, 
American College of Cardiology - National Cardiovascular Data Registry, Bethesda, MD
Background: Prior studies have compared the efficacy of inter-hospital transport for pri-
mary percutaneous coronary intervention (PCI) versus immediate thrombolysis at a non-
PCI institution in the setting of acute myocardial infarction. The role of thrombolytics prior
to transfer has not been clearly defined and remains controversial. The objective of this
study was to compare outcomes in patients with ST segment elevation MI (STEMI) trans-
ferred with or without thrombolytic therapy for PCI to a referral institution.
Methods: Between January 1, 2001 and March 31, 2003, data on 278,105 PCI proce-
dures were submitted from 304 institutions to the American College of Cardiology
National Cardiovascular Data Registry (ACC-NCDR). Of these, 15,832 involved STEMI
patients transferred for PCI. Thrombolytic therapy was initiated in 8,326 (52.6%) and
7,506 (47.4%) were transferred without thrombolytics. Multiple post-PCI outcomes such
as mortality, emergent surgery and renal failure were analyzed following PCI at the pri-
mary institution. 
Comparison of Treatments
 Women  Men Adjusted OR (95% CI)
Acute Interventions, n (%)
Aspirin 11,960 (89.6) 18,362 (91.6) 0.87 (0.81- 0.93)
Heparin (any) 10,929 (80.0) 16,993 (84.0)  0.92 (0.88-0.98)
Beta blocker 10,007 (75.8) 15,196 (77.7)  0.99 (0.94-1.04)
ACE inhibitor 5,551 (42.4) 8,176 (42.2)  0.95 (0.91-1.00)
GP IIb-IIIa inhibitor 3,574 (28.7) 7,261 (38.6)  0.86 (0.82-0.92)
Procedure Use, n (%)
Diagnostic cath 8,701 (60.1) 15,106 (71.1)  0.86 (0.81-0.91)
PCI 4,516 (31.4) 8,555 (40.4)  0.91 (0.86-0.96)
CABG 1,284 (9.0) 2,941 (14.0)  0.59 (0.54-0.64)
One year cumulative costs (Euros) and events (n,%)
PCA PHT P value
Cardiac death 12 (8.4) 12 (8.2) NS
Recurrence of non fatal MI 7 (4.9) 12 (8.2) NS
Stroke 2 (1.4) 3 (2.0) NS
Death + MI + Stroke (MACEs) 20 (14.0) 24 (16.4) NS
MACEs + unscheduled revascularization 43 (31.8) 85 (61.1) 0.001
Median 1 year cumulative cost /patient 7427 8478 0.04
